When Will Qutenza Be Available as Generic Capsaicin?

Dr. Brian Staiger, PharmD, BCPS

This page is aggregated from FDA records, court filings and company announcements. Coded and designed by

Updated November 6, 2026 How we build our data Disclaimer about this tool

Qutenza Generic at a Glance

Four quick answers from FDA records and our estimate.

  1. When will a generic be in pharmacies? March 2030 How sure: Toss-upWhat each rating means Why then?
  2. Has the FDA approved a generic? Not yet None in the FDA’s records yet Why not yet?
  3. When does the last patent end? March 2030 2 patents listed with the FDA
  4. Can you buy a generic today? Not yet None listed with the FDA

Explains

PharmD, BCPS · Clinical pharmacist Updated

The generic for Qutenza (capsaicin) is expected to reach pharmacies in March 2030, about 3.5 years away. None is in pharmacies yet.

Why March 2030?

It is when Qutenza’s patent 8,821,920 ends. That patent covers the product’s formulation, and once it ends, generics can go on sale as soon as the FDA approves them. We rate this timing toss-up: still unsettled. Just as likely to slip as to hold.

Why hasn’t the FDA approved a generic yet?

That is normal before a launch. The FDA usually can’t give a generic its final approval while a patent or exclusivity still blocks it, so final approval often comes close to the day the generic can be sold. No company holds a “tentative” approval yet either (the FDA’s word for a generic that is ready but still blocked).

What should I do now?

Keep taking Qutenza as prescribed. When a generic arrives, your pharmacy may switch you to it automatically, and it may look different. What a generic means for you

Our month is only an estimate based on available information, so we never name a day.

Qutenza by the Numbers

Reason
Patent expiresA patent that protects the brand runs out. After that, approved generics can be sold. Why March 2030?
How sure
Toss-upWhat each rating means
Price competition
Not reportedFiler count not reported
Medicare & Medicaid spend
$40M a year
  • FDA approved 2009 In November, 17 years ago FDA Orange Book
  • Patents listed 2 last runs to March 2030 FDA Orange Book
  • Medicare Part D spent $27.8M in 2025, for 4,490 people CMS Part D Spending by Drug
  • Medicaid prescriptions 3,626 in the last four reported quarters, $12.4M CMS Medicaid drug utilization, to Q1 2026

Qutenza’s Road to a Generic

Qutenza has had the market to itself since the FDA approved it in November 2009 (Averitas Pharma Inc). Its 2 listed patents run to March 2030.

The first generic of Qutenza is expected in pharmacies in March 2030.

Why that month: patent 8,821,920, on the product’s formulation, ends then.

Brand alone on the market Since FDA approval, November 2009
Patent 9,226,903 Expires December 2028
Patent 8,821,920 Expires March 2030 The patent behind the expected month of generic availability
Brand alone on the market Patent on the formulation First generic expected Swipe the chart sideways to see every year.

How to read this chart

  • The top bar: Qutenza on sale with no generic, from its FDA approval to the month we expect one.
  • Each bar below it: a patent or other FDA protection, ending the day it runs out.
  • The shaded band: the month we expect the first generic. We give a month, not a day, because the date can move, and a new generic can take a few weeks to reach pharmacies.
  • Where the dates come from: the bars from the FDA Orange Book, the expected month from court records and company announcements.

Qutenza Patents and FDA Protections

Every patent and exclusivity the FDA Orange Book lists for Qutenza’s own applications. A protection running past the expected month does not mean the date is wrong: a settlement or a court ruling can let a generic in before a patent ends, and a patent on one formulation or use does not block every generic.

The one that matters for a generic launch: patent 8,821,920, which ends in March 2030, the month the first generic is expected.

Patents listed with the FDA (2)
PatentWhat it coversProtects untilStatus
9,226,903 (opens on Google Patents) The product’s formulation December 2028 Active
8,821,920 (opens on Google Patents) Sets the expected month of generic availability The product’s formulation March 2030 Active

Source: FDA Orange Book, application 022395. Patent numbers open the patent on Google Patents.

Who Is Lined Up to Make Generic Capsaicin

How many companies have applied to make a generic is not reported. The FDA has not approved one yet. None is in pharmacies yet.

  1. Applied to the FDA Not reported
  2. Tentatively approved Ready, but a patent or exclusivity still blocks final approval None
  3. Approved by the FDA Approval is permission to sell, not a launch None yet
  4. In pharmacies None yet

How a Generic Gets From an Application to a Pharmacy

Three steps stand between a brand and a generic you can buy: a company applies to the FDA, the FDA approves it, and the company starts selling it. The last two can be years apart: patents, court rulings and settlements between the companies decide when a company may start selling.

1

Applied to the FDA

How many companies have applied to make a generic is not reported for Qutenza.

2

Approved by the FDA

Not yet. The FDA has not approved a generic capsaicin. Final approval often comes close to the day a generic can be sold.

3

For Sale in Pharmacies

Not yet. No company lists a generic capsaicin with the FDA, so none is in pharmacies.

Sources: how many companies have applied, from court records and company announcements; approved generics from the FDA Orange Book; tentative approvals from Drugs@FDA; what pharmacies are buying from NADAC, the national survey of what pharmacies pay; listings from the FDA NDC Directory. The FDA does not disclose an application before it approves it (21 CFR 314.430).

Qutenza Price: What Pharmacies Pay and What Generics Usually Do

What a Generic Could Cost

How we project it. The national survey of what pharmacies pay (NADAC) has no recent price for Qutenza, so we cannot show dollars. The FDA found that the price pharmacies pay falls about 31% with one generic company, 44% with two, 73% with four and over 95% with six or more. How many companies have applied is not reported for Qutenza, so here is the whole pattern.

What pharmacies paid as more companies sold a generic, in the FDA’s study

Source: the FDA’s 2019 study “Generic Competition and Drug Prices”, the median price pharmacies paid for a generic against the brand’s price before generics. At the manufacturer’s price the FDA found steeper drops (about 39%, 54%, 79% and over 95%), the figures quoted elsewhere on this tracker.

What Medicare and Medicaid Spend on Qutenza

Big public spending is part of why generic makers line up for a medicine, and why its first generic matters beyond the pharmacy counter. These figures are before the rebates drug companies pay back to Medicare drug plans and state Medicaid programs. The companies and the programs do not make those rebates public, so no published figure includes them.

Medicare Part D Spending

What Medicare drug plans spent on Qutenza, before manufacturer rebates.

$6.2M
January to March 2026, the latest CMS has posted
For 1,748 people, about $3,489 per prescription fill
$27.8M
2025, the whole year
For 4,490 people, about $3,450 per prescription fill
See the numbers
PeriodSpendingPeoplePer fill
January to March 2026$6,213,2431,748$3,488.63
2025$27,758,8424,490$3,449.59

Source: CMS Medicare Part D Spending by Drug, matched by the brand name Qutenza only, so no generic is counted in it.

Medicaid Prescriptions by Quarter

3,626 prescriptions in the four quarters to Q1 2026, $12.4M paid.

See the numbers
QuarterPrescriptionsMedicaid paid
Q1 2026877$4,359,785
Q4 2025868$2,603,182
Q3 20251,087$3,422,564
Q2 2025794$2,023,441
Q1 2025763$1,818,021

Source: CMS Medicaid State Drug Utilization Data, over Qutenza’s own package codes.

Qutenza Strengths and Forms

StrengthFormHow it is takenApprovedStatus
8%PatchTopicalNovember 2009Prescription reference product

Source: FDA Orange Book, Averitas Pharma Inc. Listed in the FDA NDC Directory today by Averitas Pharma Inc.

Qutenza NDC Codes and Packages

Each Qutenza package sold today has its own NDC, the product number printed on the box and on the pharmacy label. Open one to see that package’s details, what pharmacies pay for it and its patent timeline.

Qutenza packages (3)
NDCProductPackageCompany
72512-0928-01kit1 KIT in 1 CARTON * 1 POUCH in 1 CARTON / 1 PATCH in 1 POUCH / 179 mg in 1 PATCH * 50 g in 1 TUBEAveritas Pharma Inc
72512-0929-01kit1 KIT in 1 CARTON * 2 POUCH in 1 CARTON / 1 PATCH in 1 POUCH / 179 mg in 1 PATCH * 50 g in 1 TUBEAveritas Pharma Inc
72512-0930-01kit1 KIT in 1 CARTON * 4 POUCH in 1 CARTON / 1 PATCH in 1 POUCH / 179 mg in 1 PATCH * 3 TUBE in 1 CARTON / 50 g in 1 TUBEAveritas Pharma Inc

Source: the FDA NDC Directory, current listings only. Only packages sold under Qutenza’s own FDA approval (NDA 22395) are listed, never a generic. Some codes belong to companies that repackage Qutenza: it is the same medicine in a different package.

What a Generic Qutenza Means for You

Nothing Changes Until It Is in Pharmacies

Until a generic is actually in pharmacies, keep filling Qutenza as usual. An FDA approval alone does not put one there. When one arrives, there is nothing you need to sign up for.

Your Pharmacy May Switch You Automatically

Every state lets pharmacists fill a brand-name prescription with an FDA-approved generic rated as equivalent to it, and about 19 states require them to, unless your prescriber writes “dispense as written” or “brand medically necessary” on the prescription. Some states ask the pharmacist to tell you, or to get your OK first. A study of every state’s law has the details.

It Will Probably Look Different

US trademark law does not let a generic look exactly like the brand, so the color, shape or markings usually change. The active ingredient, strength and form are the same. An “authorized generic,” made by or for the brand’s own company, can look identical. The FDA explains.

Your Insurance May Change Too

Once a lower-cost version is available, many insurance plans charge more for the brand, or stop covering it. Your plan’s drug list (formulary) says how.

Until a generic is on US pharmacy shelves, be careful with websites that offer “generic Qutenza”. The FDA warns that unlicensed online pharmacies sell counterfeit and unapproved medicines; its BeSafeRx page shows how to check a pharmacy.

Questions people ask about Qutenza

Is there a generic for Qutenza right now?

No. The FDA’s drug directory (as of November 19, 2026) shows no company listing a generic capsaicin, so none is in pharmacies. The first generic is expected in pharmacies in March 2030, about 3.5 years away.

When will Qutenza go generic?

March 2030 is the month the first generic is expected in pharmacies, though that is still a toss-up. It is when Qutenza’s patent 8,821,920 ends. That patent covers the product’s formulation, and once it ends, generics can go on sale as soon as the FDA approves them.

Will generic capsaicin be the same as Qutenza?

The active ingredient, strength and dosage form must match, and the generic must meet FDA standards for equivalence. Inactive ingredients and appearance may be different.

How much will the generic cost?

There is no confirmed generic price before launch. How many companies have applied to make one is not reported; in general, the more companies sell a generic, the further the price falls.

Has the FDA approved a generic Qutenza?

Not yet. The FDA Orange Book lists no approved generic version of Qutenza.

When does the Qutenza patent expire?

The FDA Orange Book lists 2 patents for Qutenza; the last runs to March 2030. The one behind the expected month is patent 8,821,920, which ends in March 2030. A patent date is not the launch date: settlements and court rulings often bring a generic earlier, and FDA approval or a company’s own plans can make it later. The expected month on this page (March 2030) weighs all of that.

Changes to This Projection

  • First generic expected March 2030 on this month’s schedule. A line is added here whenever a monthly update moves the month, the reason or how sure it is.

Every change to the expected month is logged here with the month we saw it.

What Each “How Sure” Rating Means

How sure says how firm the expected month is, on four steps shown by the boxes. It is a rating, not a percent chance: court rulings, FDA reviews and companies’ own plans can move any date. We review every rating each month.

  • Very likely, 4 of 4 boxes filled

    Few things could still move it, but a court ruling or a new deal can.

    Usually because a settlement with a public date or an FDA exclusivity ending sets the month, and generic companies have applied.

  • Likely, 3 of 4 boxes filled

    Firm enough to plan around, but a court ruling or a new deal could still move it.

    Usually because a settlement with a public date, or the last listed patent or protection ending, sets the month, and companies have applied.

  • Probable, 2 of 4 boxes filled

    More likely than not, but it can still move.

    Usually because a patent or protection ending sets the month, but few generic companies are on record yet, or the product is hard to copy.

  • Toss-up, 1 of 4 boxes filled

    Still unsettled. Just as likely to slip as to hold.

    Usually because no generic company is on record yet, the patents are challenged with nothing settled, or a settlement has no public date.

  • Not rated, no boxes filled

    Too early to rate. The month is where the records point today.

    Usually because nothing public sets a month yet.

Back to Qutenza Generic at a Glance

Also Going Generic

All upcoming generics

About Qutenza

  • Generic name capsaicin
  • How it is taken On the skin
  • Company Averitas Pharma Inc
  • Hard to copy Inhalers, injectables, patches and other hard-to-copy products. Fewer companies attempt them and dates slip more often.
  • More drugs Brand-name drugs starting with Q
  • Have a question? A pharmacist answers, free. Ask about Qutenza

Sources. The expected month: FDA Paragraph IV Patent Certifications list, federal court records, company announcements and securities filings (settlement dates, launch plans, sales). The record on this page: FDA Orange Book, Drugs@FDA (tentative approvals), FDA NDC Directory, CMS Medicare Part D Spending by Drug, Medicaid State Drug Utilization Data, FDA, Generic Competition and Drug Prices (2019). Updated November 6, 2026. Information, not medical advice.

Explains Generic Availability

Knowing when a generic will reach pharmacies is more complicated than looking up a patent expiration date. Patent lawsuits, agreements between drug companies, FDA approval, and manufacturing and supply plans can all affect the timing.

We developed proprietary algorithms to organize launch estimates alongside available patent information, FDA records and updates, information from court filings, and public company communications. The explanations update automatically from the tracker’s data. We show or summarize key supporting details on this page, with source links where available, to help you understand the projection and its limitations.

We give a projected month rather than an exact day. We cannot guarantee that every projection will be correct: new information or changes in plans can move the date earlier or later. Even after FDA approval, a generic may not yet be available at your pharmacy. Check with your pharmacist about current availability.

How we build our data Back to top